Home / Expertise / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

Italy

CMS Adonnino Ascoli & Cavasola Scamoni has developed a broad expertise in the field of life sciences. The firm's life sciences practice includes the assistance of clients which operate in the fields of pharmaceuticals, biotechnology medical devices and more generally health care services. We regularly advise life science companies on corporate governance matters and licensing and contracts, as well as day-to-day corporate issues. The Team can count on professionals “borrowed” on a regular basis, to life sciences from other departments of the firm including team of corporate and intellectual property professionals who can boast a significant experience securing and defending patent positions and regulatory law issues in order for companies to comply with the Italian regulatory law.

Read more Read less

Choose area

    Pharmaceuticals

    Today the pharmaceutical industry is rapidly growing. This is a highly complex industry and represents one of the fastest growing on the market.

    Read more

    Feed

    Show only
    09/04/2019
    CMS al fianco della so­ci­età belga Medi-Mar­ket S.A....
    31 Jan 20
    UK In­tel­lec­tu­al Prop­erty Of­fice finds that pat­ent law does not cater...
    The UK In­tel­lec­tu­al Prop­erty Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The UKIPO ac­cep­ted the in­dic­a­tion...
    06/03/2019
    The European Com­mis­sion sets new rules for the qual­ity...
    17 Jan 20
    New guid­ance on cy­ber­se­cur­ity for med­ic­al devices pub­lished
    In Decem­ber 2019, the Med­ic­al Device Co­ordin­a­tion Group (“MD­CG”) is­sued a new guid­ance to help med­ic­al device man­u­fac­tur­ers meet the cy­ber­se­cur­ity re­quire­ments in the Med­ic­al Devices Reg­u­la­tion (“MDR”)...
    01/02/2019
    Get­ting the Deal Through – Life Sci­ences 2019
    15 Jan 20
    Can newly dis­covered can­nabis com­pounds be pro­tec­ted by pat­ents?
    A break­through dis­cov­ery has re­cently hit the news: tet­rahy­drocan­nabi­phorol (THCP) and can­na­bid­i­phorol (CB­DP), two new can­nabin­oid com­pounds, have been dis­covered in Can­nabis sativa and char­ac­ter­ised...
    06/06/2018
    European Com­mis­sion pro­poses SPC ex­emp­tions for gen­er­ics...
    23 Dec 19
    So­cial Me­dia and mHealth Data EMA / HMA Re­port
    New and in­nov­at­ive tech­no­lo­gies have led to a huge in­crease in data com­ing from sources that haven’t pre­vi­ously been used with­in the reg­u­lated medi­cines in­dustry. In re­cog­ni­tion of this ex­plo­sion of...
    01/02/2018
    Get­ting the Deal Through - Life Sci­ences 2018
    20 Dec 19
    ‘Dar­unavir’ CJEU re­fer­ral with­drawn - Art­icle 3(a) of the SPC Reg­u­la­tion
    At the end of Septem­ber, we re­por­ted here on the pub­lic­a­tion of AG Hogan’s Opin­ion on the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from...
    11/01/2017
    Get­ting the Deal Through – Life Sci­ences 2017
    17 Dec 19
    The rise of pat­ent wars in Europe’s gene ther­apy space
    The gene ther­apy in­dustry is in an ex­cit­ing phase of growth, un­der­go­ing sig­ni­fic­ant M&A activ­ity, product sales and new mar­ket­ing au­thor­isa­tions that are be­ing is­sued with in­creas­ing reg­u­lar­ity glob­ally....